TIDMAPH

RNS Number : 0943K

Alliance Pharma PLC

19 June 2014

 
 For immediate release   19 June 2014 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Exercise of Share Options

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that following the exercise of employee share options on 19 June 2014, application has been made by Alliance for a further 10,492 ordinary shares of 1 pence each in the Company ("Ordinary Shares") to be admitted to trading on AIM.

It is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 25 June 2014.

Following the exercise of the options, Alliance will have 264,148,365 Ordinary Shares in issue.

For further information:

 
 Alliance Pharma plc                           + 44 (0) 1249 466966 
 John Dawson, Chief Executive 
 Richard Wright, Finance Director 
 
 Buchanan                                     + 44 (0) 20 7466 5000 
 Mark Court / Fiona Henson / Sophie Cowles 
 
 Numis Securities Limited                     + 44 (0) 20 7260 1000 
 Nominated Adviser: Michael Meade / Oliver 
  Cardigan/Freddie Barnfield 
 Corporate Broking: David Poutney 
 

Notes to editors:

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSLLFVRRIIALIS

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alliance Pharma Charts.